A Trial Using CD133 Enriched Bone Marrow Cells Following Primary Angioplasty for Acute Myocardial Infarction

Inclusion Criteria: * Primary PCI for acute STEMI between 2-24 hours after onset of chest pain. * ST-segment elevation \>=2mm in \>=3 adjacent leads. * Presence of severe hypokinesia and/or akinesia in \>=2 adjacent segments on echocardiogram at 48-72 hrs after primary PCI. * Age between 20 and 75 years. Exclusion Criteria: * Pregnant or lactating. * Prior history of myocardial infarction before index event. * Decompensated congestive heart failure. * Pre-existent LV dysfunction (EF \<45% prior to admission) * Cardiomyopathy. * Previous cardiac surgery. * Congenital heart disorder. * Serum creatinine \>200 Mmol/L. * Presence of permanent pacemaker or implantable defibrillator. * Contraindication to bone marrow aspiration. * History of malignancy within 5 years except curatively treated basal cell carcinoma, squamous cell carcinoma and/or cervical carcinoma. * Sustained or inducible VT \>48 hours post primary PCI. * Three vessel coronary artery disease necessitating intervention within 4 months. * Immune compromise including chronic human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. * Presence of chronic systemic inflammatory disorders. * Previous autologous or allogeneic bone marrow or peripheral stem cell transplant or prior solid organ transplantation. * Low hemoglobin, white blood cell, absolute neutrophil and/or platelet count. * Any condition associated with a life expectancy of less than 6 months. * Participation in unrelated research involving investigational pharmacological agent(s) 30 days before planned dosing. * Current alcohol or drug abuse. * Inability to provide written informed consent.